Protagenic Therapeutics updates clinical milestones; plans US re-submission and Phase I/IIa trial in Germany by Q3 2022

Protagenic Therapeutics, Inc.new

Company completing requirements to answer regulatory questions and begin US re-submission process.
Submitting filing in Europe to commence Phase I/IIa trial at a major CRO site in Germany anticipated to start Q3 2022.
Further updates to clinical development schedule to be provided as it becomes clearer.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.